Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

July 9, 2024
Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose
Read
4 min read
July 1, 2024
Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location
"Skyhawk has achieved tremendous scientific advances in our Basel Switzerland location so far," said Sergey Paushkin, CSO
Read
2 min read
June 11, 2024
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
Skyhawk today announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and
Read
4 min read
April 22, 2024
Ipsen, Skyhawk ink deal worth up to $1.8B
Ipsen, Skyhawk Therapeutics pen neurological deal: Ipsen and Skyhawk plan to develop small molecules that can modulate RNA in a deal...
Read
1 min read
April 22, 2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following...
Read
2 min read